Serum Institute of India, the leading vaccine maker, has developed a heat-stable rotavirus vaccine named Rotasiil in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID).
Rotasiil is an oral vaccine administered to infants in a three-dose course at the ages of 6, 10, and 14 weeks.
The vaccine will revolutionize healthcare for children across the globe due to its potency, longevity and ability to endure severe changes in temperature, thereby reducing wastage and storage costs, the company said in a release. It is the only rotavirus vaccine to have the ability to withstand extreme temperatures. It can be stored at temperatures up to 25°C throughout its shelf life of 30 months.
Serum’s BRV-PV contains bovine-human reassortant rotaviruses against the most common rotavirus serotypes (G1, G2, G3, G4, and G9).
The bovine-human reassortant rotavirus vaccine was developed by the US National Institutes of Health and licensed to up to ten emerging-country manufacturers for further development. Serum was one of the licensees and developed a pentavalent vaccine BRV-PV.